Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma

Oncology
Gennaro CormioLuigi Selvaggi

Abstract

To evaluate the activity and toxicity of the combination of cisplatin and vinorelbine in patients with recurrent carcinoma of the vulva that has not been previously treated with chemotherapy. Sixteen women with a median age of 65 years (range 43-79) with recurrent vulvar carcinoma were enrolled in the study. Nine patients had local recurrent disease (perineum, vagina and/or vulva), whereas 7 had disease in the groin; 9 patients had received prior radiotherapy. Cisplatin was administered intravenously on day 1 and vinorelbine was given on day 1 immediately after cisplatin and on day 8. A total of 68 cycles of chemotherapy were administered. Fifteen women were assessed for response. Objective responses were recorded in 6 patients (40%) - with 4 patients (27%) achieving a complete response and 2 (13%) achieving a partial response -, whereas 4 patients (27%) had stable disease and 5 had progressive disease. The median progression-free survival was 10 months (range 3-17), whereas the overall survival from the beginning of the chemotherapy was 19 months (range 1-30). Due to the small number of patients, no significant correlation with site of recurrence could be found. The combination of cisplatin and vinorelbine is a well-tolerated ...Continue Reading

Citations

Oct 16, 2013·Current Oncology Reports·Kathryn Graham, Kevin Burton
Mar 23, 2013·Wiener klinische Wochenschrift·Gunter DeppeIra S Winer
Jan 17, 2012·Hematology/oncology Clinics of North America·Katherine C Fuh, Jonathan S Berek
May 24, 2011·Critical Reviews in Oncology/hematology·Federica TomaoPierluigi Benedetti Panici
Apr 23, 2014·The Journal of Obstetrics and Gynaecology Research·Gunter DeppeIra S Winer
Jul 4, 2012·Gynecologic Oncology·N S HorowitzD S Dizon
Jul 8, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Linn WoelberSven Mahner
Jul 13, 2016·Gynecologic Oncology·Katharina PrieskeLinn Woelber
Sep 18, 2016·Critical Reviews in Oncology/hematology·L S NooijM I E van Poelgeest
May 2, 2013·Therapeutic Advances in Medical Oncology·Linn WoelberSven Mahner
Nov 22, 2017·International Journal of Clinical Oncology·Toshiaki SaitoHidetaka Katabuchi
Oct 6, 2011·British Journal of Cancer·F HintenJ A de Hullu
May 23, 2015·Expert Review of Anticancer Therapy·Sven MahnerLinn Woelber
Mar 23, 2019·Bulletin du cancer·Henri AzaïsUNKNOWN Groupe transversal sein-gynécologie AP–HP
Aug 28, 2021·Cancers·Marco MazzottaPatrizia Vici

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.